Likewise, inhibition of RBBP4 does not impact CML or T-ALL cell but rather inhibits AML cell growth in a manner similar to that seen after RNF5 inhibition. Here, RNF5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.